EBS

Emergent BioSolutions Inc. [EBS] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

EBS Stock Summary

Top EBS Correlated Resources

EBS


Top 10 Correlated ETFs

EBS


Top 10 Correlated Stocks

EBS


In the News

12:48 08 Dec 2022 EBS

Emergent (EBS) OTC Narcan Filing Gets FDA Priority Review Tag

The FDA grants priority review to Emergent's regulatory filing seeking approval for an OTC version of its Narcan nasal spray. A final decision is expected by March 2023-end.

09:02 08 Dec 2022 EBS

4 Toxic Stocks More So Hazardous Amid Volatile Times

Just like identifying stocks with growth potential, pinpointing toxic stocks and offloading them at the right time is crucial to guard one's portfolio from big losses. EBS, WDC, TWKS and DZSI are a few such toxic stocks.

12:02 08 Dec 2022 EBS

Emergent's (EBS) Q3 Earnings and Revenues Miss Estimates

Emergent's (EBS) third-quarter 2022 earnings and revenues miss estimates. EBS issues fresh guidance for its CDMO services

09:47 08 Dec 2022 EBS

Emergent BioSolutions Inc. (EBS) Q3 2022 Earnings Call Transcript

Emergent BioSolutions Inc. (NYSE:EBS ) Q3 2022 Earnings Conference Call November 8, 2022 5:00 PM ET Company Participants Bob Burrows - Vice President, Investor Relations Bob Kramer - President & Chief Executive Officer Rich Lindahl - Chief Financial Officer Conference Call Participants Jessica Fye - JPMorgan Keay Nakae - Chardan Brandon Folkes - Cantor Operator Good day and thank you for standing. Welcome to the Emergent BioSolutions Third Quarter 2022 Earnings Conference Call.

09:04 08 Dec 2022 EBS

Emergent Biosolutions (EBS) Reports Q3 Loss, Misses Revenue Estimates

Emergent Biosolutions (EBS) delivered earnings and revenue surprises of -2,016.67% and 10.51%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

02:05 08 Dec 2022 EBS

Ranking the 7 Top Small-Cap Stocks to Buy From Best to Worst

These top small-cap stocks to buy present daring investors with significant upside. Fundamentally, companies with a relatively diminutive profile typically command higher growth potential.

06:30 08 Dec 2022 EBS

Emergent BioSolutions to Release Third Quarter 2022 Financial Results and Conduct Conference Call on November 8, 2022

GAITHERSBURG, Md., Oct. 18, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Tuesday, November 8, 2022, at 5:00 pm eastern time to discuss the financial results for the third quarter of 2022, recent business developments, and financial outlook for full year 2022.

12:48 08 Dec 2022 EBS

Emergent Biosolutions (EBS) Down 20% Since Last Earnings Report: Can It Rebound?

Emergent Biosolutions (EBS) reported earnings 30 days ago. What's next for the stock?

11:40 08 Dec 2022 EBS

3 Top Monkeypox Stocks to Buy Right Now

With the latest outbreak now reported in all 50 states per ABC News, investors may want to consider the top monkeypox stocks to buy right now. From an investment perspective, this latest health threat poses powerful catalysts.

06:30 08 Dec 2022 EBS

Emergent BioSolutions to Participate in Investor Conferences

GAITHERSBURG, Md., Aug. 10, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that members of the company's executive management team will participate in the following investor conferences:

EBS Financial details

Company Rating
Buy
Market Cap
598.66M
Income
53.5M
Revenue
1.51B
Book val./share
29.04
Cash/share
4.83
Dividend
-
Dividend %
-
Employees
2.42K
Optionable
No
Shortable
Yes
Earnings
09 Jan 2023
P/E
7.33
Forward P/E
1
PEG
-0.85
P/S
0.41
P/B
0.43
P/C
2.62
P/FCF
9.77
Quick Ratio
1.61
Current Ratio
4.17
Debt / Equity
0.71
LT Debt / Equity
0.71
-
-
EPS (TTM)
0.82
EPS next Y
12.72
EPS next Q
4.44
EPS this Y
-25.39%
EPS next Y
1451.22%
EPS next 5Y
1451.22%
EPS last 5Y
16.89%
Revenue last 5Y
26.16%
Revenue Q/Q
-1.11%
EPS Q/Q
34.51%
-
-
-
-
SMA20
-33.33%
SMA50
-42.86%
SMA100
-61.29%
Inst Own
80.25%
Inst Trans
-0.3%
ROA
2%
ROE
3%
ROC
0.06%
Gross Margin
55%
Oper. Margin
11%
Profit Margin
4%
Payout
-
Shs Outstand
49.89M
Shs Float
44.8M
-
-
-
-
Target Price
51.5
52W Range
11.34-52.28
52W High
-75.65%
52W Low
+15.09%
RSI
40
Rel Volume
0.59
Avg Volume
796.23K
Volume
470.43K
Perf Week
2.93%
Perf Month
-39.34%
Perf Quarter
-56.57%
Perf Half Y
-58.9%
-
-
-
-
Beta
1.037
-
-
Volatility
0.3%, 3.59%
Prev Close
2.26%
Price
12.66
Change
4.46%

EBS Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2021-12-31

Metric History 2017-12-312018-12-312019-12-312020-12-31 2021-12-31
Revenue per share
13.4115.6221.4829.5134.02
Net income per share
1.981.251.065.794.38
Operating cash flow per share
4.980.833.6510.176.09
Free cash flow per share
3.67-0.61.967.51.82
Cash per share
4.262.243.2611.7910.93
Book value per share
21.8220.1821.1427.4630.72
Tangible book value per share
17.78-1.211.559.8114.98
Share holders equity per share
21.8220.1821.1427.4630.72
Interest debt per share
0.4816.0616.517.1916.61
Market cap
2.08B3.03B2.84B5.63B2.39B
Enterprise value
1.92B3.72B3.49B5.88B2.65B
P/E ratio
25.2448.3752.1418.4610.34
Price to sales ratio
3.723.882.573.621.33
POCF ratio
10.0272.5615.1210.517.43
PFCF ratio
13.6-100.128.1114.2624.84
P/B Ratio
2.2932.613.891.47
PTB ratio
2.2932.613.891.47
EV to sales
3.424.753.153.781.48
Enterprise value over EBITDA
11.4424.1915.3910.645.61
EV to operating cash flow
9.2388.8918.5410.988.26
EV to free cash flow
12.52-122.6234.4714.927.6
Earnings yield
0.040.020.020.050.1
Free cash flow yield
0.07-0.010.040.070.04
Debt to equity
0.010.780.730.580.5
Debt to assets
0.150.550.530.50.45
Net debt to EBITDA
-0.984.442.840.460.56
Current ratio
4.853.13.173.113.4
Interest coverage
18.869.072.9713.8610.22
Income quality
2.520.673.451.761.39
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
0.260.260.250.190
Research and developement to revenue
0.170.180.20.150.13
Intangibles to total assets
0.160.480.430.320.28
Capex to operating cash flow
-0.26-1.72-0.46-0.26-0.7
Capex to revenue
-0.1-0.09-0.08-0.09-0.13
Capex to depreciation
-1.29-1.16-0.79-1.23-1.82
Stock based compensation to revenue
0.030.030.020.030.02
Graham number
31.1423.8422.4359.855.03
ROIC
0.130.040.050.170.14
Return on tangible assets
0.090.050.040.160.11
Graham Net
4.82-15.97-14.63-9.26-7.26
Working capital
385.32M420.4M469.9M811.4M898.3M
Tangible asset value
743.62M-60.4M80M517.2M789.5M
Net current asset value
327.53M-597.7M-552.6M-240.3M-67.9M
Invested capital
0.010.790.750.60.52
Average receivables
188.49M251M253.1M230.9M252.8M
Average payables
88.93M108.4M115.45M136.1M132.5M
Average inventory
224.91M256.4M264.75M307M328.9M
Days sales outstanding
95.07126.4790.8554.1855.93
Days payables outstanding
77.8791.3979.8294.862.11
Days of inventory on hand
266.35233.07187.34213.85169.03
Receivables turnover
3.842.894.026.746.53
Payables turnover
4.693.994.573.855.88
Inventory turnover
1.371.571.951.712.16
ROE
0.090.060.050.210.14
Capex per share
-1.31-1.44-1.69-2.68-4.27

Quarterly Fundamentals Overview

Last date of statement is 2022-09-30 for Q3

Metric History 2021-09-302021-12-312022-03-312022-06-30 2022-09-30
Revenue per share
6.1313.526.074.854.81
Net income per share
-0.613.54-0.07-1.13-1.52
Operating cash flow per share
0.316.15-0.74-0.31-1.48
Free cash flow per share
-0.725.28-1.37-0.95-2.04
Cash per share
7.5210.778.67.164.83
Book value per share
28.3630.2631.0730.2629.04
Tangible book value per share
11.8714.7614.9914.2310.05
Share holders equity per share
28.3630.2631.0730.2629.04
Interest debt per share
15.9615.8916.5916.6621.28
Market cap
2.69B2.33B2.08B1.55B1.05B
Enterprise value
3.13B2.59B2.48B2.02B1.86B
P/E ratio
-20.563.07-140.66-6.88-3.46
Price to sales ratio
8.173.226.776.394.36
POCF ratio
1617.07-55.81-99.49-14.15
PFCF ratio
-69.848.24-29.95-32.54-10.28
P/B Ratio
1.771.441.321.030.72
PTB ratio
1.771.441.321.030.72
EV to sales
9.533.588.068.327.75
Enterprise value over EBITDA
-712.248.4770.23-66.2-80.51
EV to operating cash flow
187.667.87-66.46-129.43-25.13
EV to free cash flow
-81.49.18-35.67-42.33-18.25
Earnings yield
-0.010.080-0.04-0.07
Free cash flow yield
-0.010.12-0.03-0.03-0.1
Debt to equity
0.540.50.510.520.71
Debt to assets
0.470.450.430.450.5
Net debt to EBITDA
-101.160.8711.25-15.31-35.17
Current ratio
3.043.44.423.924.17
Interest coverage
-4.1330.820.78-9.23-4.94
Income quality
-0.511.7410.080.280.98
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
00000
Research and developement to revenue
0.150.110.150.210.16
Intangibles to total assets
0.310.280.290.290.33
Capex to operating cash flow
-3.31-0.140.862.060.38
Capex to revenue
-0.17-0.06-0.1-0.13-0.12
Capex to depreciation
-1.69-1.6-1.04-0.72-0.86
Stock based compensation to revenue
0.030.010.030.050.05
Graham number
19.7149.087.1427.7131.49
ROIC
-0.010.110-0.03-0.02
Return on tangible assets
-0.020.090-0.03-0.04
Graham Net
-10.57-7.15-8.53-10.4-16.07
Working capital
746.1M898.3M851.1M807.5M850.1M
Tangible asset value
637.6M789.5M759.8M711.7M501.7M
Net current asset value
-233.3M-67.9M-104.8M-138M-340.7M
Invested capital
0.560.520.530.550.73
Average receivables
214.8M224.85M178.4M175M183.15M
Average payables
120.7M117.55M106.75M106.2M105M
Average inventory
395.05M388.15M413.1M425.5M485.9M
Days sales outstanding
69.6534.1953.2164.8971.74
Days payables outstanding
55.9454.4961.9456.2962.87
Days of inventory on hand
150.87148.29231.32225.53330.87
Receivables turnover
1.292.631.691.391.25
Payables turnover
1.611.651.451.61.43
Inventory turnover
0.60.610.390.40.27
ROE
-0.020.120-0.04-0.05
Capex per share
-1.03-0.87-0.64-0.64-0.56

EBS Frequently Asked Questions

What is Emergent BioSolutions Inc. stock symbol ?

Emergent BioSolutions Inc. is a US stock , located in Gaithersburg of Maryland and trading under the symbol EBS

Is Emergent BioSolutions Inc. buy or a sell ?

2 stock analysts have 2 predictions with a medium analyst target price of $51.5. The lowest prediction is $38 and the highest is $65

What is EBS stock prediction ?

What is Emergent BioSolutions Inc. stock quote today ?

Emergent BioSolutions Inc. stock price is $12.66 today.

Is Emergent BioSolutions Inc. stock public?

Yes, Emergent BioSolutions Inc. is a publicly traded company.

Something similar

Top Correlated ETFs
Top Correlated Stocks
Similar Market Cap